Open access · US-GOV via ClinicalTrials.gov Clinical trial

Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment

Authors not listed

Groupe Oncologie Radiotherapie Tete et Cou · 2013

Stem-cell exhaustion Human Randomized controlled trial

Abstract

The aim of the trial is to evaluate the clinical benefit (efficacy, safety, preservation of autonomy) of cetuximab-carboplatin-5FU combination as first line treatment of recurrent or metastatic head and neck squamous cell carcinoma in patients over 70 years without frailty (after geriatric assessment).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-07-02 MST

Cite this

APA

Anonymous. (2013). Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment. <em>Groupe Oncologie Radiotherapie Tete et Cou</em>. https://clinicaltrials.gov/study/NCT01864772

Vancouver

Anonymous. Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment. Groupe Oncologie Radiotherapie Tete et Cou. 2013.

BibTeX

@misc{anon2013PhaseI, title = {Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment}, author = {Anonymous}, journal = {Groupe Oncologie Radiotherapie Tete et Cou}, year = {2013}, }